EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
|
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Mergers and Acquisitions / Purchase of parts of a company Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH Rellingen, March 03, 2026 – Viromed Medical AG ("Viromed“; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has today signed a letter of intent to acquire all shares in relyon plasma GmbH, which is based in Regensburg (“relyon”). The purchase price is currently under negotiation, but Viromed estimates it will be in the low- to mid-double-digit million euro range. The conclusion of the corresponding share purchase agreement is expected to be concluded in the second quarter of 2026 and will be subject to a successful due diligence review and the fulfilment of customary closing conditions. relyon is a subsidiary of TDK Electronics AG and is one of the leading technology providers in the field of atmospheric plasma technology. reylon develops modular systems and customized OEM components for industrial and medical applications and has an extensive international patent portfolio in the field of plasma technology. In recent years, Viromed has worked with relyon to develop the cold plasma medical devices in the ViroCAP® and PulmoPlas® product families. In addition, relyon is currently handling the production of these systems on behalf of Viromed. Through this planned acquisition, Viromed will expand its value chain and gain direct access to reylon's expertise.
Notifying person: Uwe Perbandt, CEO Viromed Medical AG
E-Mail: kontakt@viromed-medical.de End of Inside Information
03-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Viromed Medical AG |
| Hauptstraße 105 | |
| 25462 Rellingen | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A40ZVN7 |
| WKN: | A40ZVN |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX |
| EQS News ID: | 2284950 |
| End of Announcement | EQS News Service |
|
|
2284950 03-March-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 1,37 | 9,00 | 80,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,50 | 8,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 5,56 | 10,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | -0,11 | 0,00 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 1,23 | -0,01 | -0,01 | -0,02 | 0,04 | 0,07 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Bernd Lenzen
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Viromed Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZVN | DE000A40ZVN7 | AG | 129,60 Mio € | 04.05.2022 | 9F5FMR3F+R3 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 49,23 | 0,00 | 0,00 | 320,00 | 6,49 | -1.178,18 | 94,60 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 06.07.2026 | 30.09.2024 | 30.06.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +25,47% | +50,94% | +57,89% | +244,83% | +25,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
